Next Article in Journal
Marfan Syndrome Versus Bicuspid Aortic Valve Disease: Comparative Analysis of Obstetric Outcome and Pregnancy-Associated Immediate and Long-Term Aortic Complications
Next Article in Special Issue
Microbial Analysis of Saliva to Identify Oral Diseases Using a Point-of-Care Compatible qPCR Assay
Previous Article in Journal
Predicting Stroke Outcomes Using Ankle-Brachial Index and Inter-Ankle Blood Pressure Difference
Editorial

COVID-19: A Recommendation to Examine the Effect of Mouthrinses with β-Cyclodextrin Combined with Citrox in Preventing Infection and Progression

1
University Lyon 1, Laboratory “Health Systemic Process”, EA4129, 69008 Lyon, France
2
Department of Public Health and Infectious Diseases, Sapienza University of Rome, 00185 Rome, Italy
3
THEnet, Training for Health Equity Network, New York, NY 10023, USA
4
Faculty of Dentistry, Estacio de Sá University, Rio de Janeiro 20261-063, Brazil
5
Lyon Public Hospices, Central Pharmacy, EA4129, 69002 Lyon, France
6
Department of Preventive and Community Dentistry, University of Granada, 18010 Granada, Spain
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2020, 9(4), 1126; https://doi.org/10.3390/jcm9041126
Received: 27 March 2020 / Accepted: 13 April 2020 / Published: 15 April 2020
(This article belongs to the Special Issue The Oral Microbiome in Health and Disease)
Considered to be a major portal of entry for infectious agents, the oral cavity is directly associated with the evolutionary process of SARS-CoV-2 in its inhalation of ambient particles in the air and in expectorations. Some new generations of mouth rinses currently on the market have ingredients that could contribute to lower the SARS-CoV-2 viral load, and thus facilitate the fight against oral transmission. If chlorhexidine, a usual component of mouth rinse, is not efficient to kill SARS-CoV-2, the use of a mouth rinses and/or with local nasal applications that contain β-cyclodextrins combined with flavonoids agents, such as Citrox, could provide valuable adjunctive treatment to reduce the viral load of saliva and nasopharyngeal microbiota, including potential SARS-CoV-2 carriage. We urge national agencies and authorities to start clinical trials to evaluate the preventive effects of βCD-Citrox therapeutic oral biofilm rinses in reducing the viral load of the infection and possibly disease progression. View Full-Text
Keywords: COVID-19; 2019-nCoV; SARS-CoV-2; oral cavity; mouthrinse; β-cyclodextrins; Citrox; viral load; microbiome COVID-19; 2019-nCoV; SARS-CoV-2; oral cavity; mouthrinse; β-cyclodextrins; Citrox; viral load; microbiome
MDPI and ACS Style

Carrouel, F.; Conte, M.P.; Fisher, J.; Gonçalves, L.S.; Dussart, C.; Llodra, J.C.; Bourgeois, D. COVID-19: A Recommendation to Examine the Effect of Mouthrinses with β-Cyclodextrin Combined with Citrox in Preventing Infection and Progression. J. Clin. Med. 2020, 9, 1126. https://doi.org/10.3390/jcm9041126

AMA Style

Carrouel F, Conte MP, Fisher J, Gonçalves LS, Dussart C, Llodra JC, Bourgeois D. COVID-19: A Recommendation to Examine the Effect of Mouthrinses with β-Cyclodextrin Combined with Citrox in Preventing Infection and Progression. Journal of Clinical Medicine. 2020; 9(4):1126. https://doi.org/10.3390/jcm9041126

Chicago/Turabian Style

Carrouel, Florence; Conte, Maria P.; Fisher, Julian; Gonçalves, Lucio S.; Dussart, Claude; Llodra, Juan C.; Bourgeois, Denis. 2020. "COVID-19: A Recommendation to Examine the Effect of Mouthrinses with β-Cyclodextrin Combined with Citrox in Preventing Infection and Progression" J. Clin. Med. 9, no. 4: 1126. https://doi.org/10.3390/jcm9041126

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop